Application of ubenimex capsule combined with FOLFOX4 regimen in the treatment of patients with primary gastric cancer and its effect on the expression of Skp2 and P27kipl protein
10.3760/cma.j.issn.1008-6706.2020.16.003
- VernacularTitle:乌苯美司胶囊联合FOLFOX4方案治疗原发性胃癌及对患者Skp2与P27kipl蛋白表达的影响
- Author:
Jia ZHENG
1
;
Xiancang SHENG
;
Hui JIN
;
Jianhua LI
Author Information
1. 浙江省，台州市第一人民医院消化内科 318020
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(16):1929-1933
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the effect of ubenimex capsule combined with FOLFOX4 on the expression of Skp2 and p27kipl in patients with primary gastric cancer.Methods:From June 2017 to June 2019, 114 patients with primary gastric cancer who hospitalized in the First People's Hospital of Taizhou were divided into observation group and control group according to the random digital table method, with 57 cases in each group.The control group was treated with FOLFOX4 chemotherapy, and the observation group was treated with ubenimex capsule on the basis of the control group.After three cycles of continuous chemotherapy, the short-term efficacy, the level of immune function index, the expression of Skp2 and p27kipl protein, and the incidence of adverse reactions were compared.Results:The objective remission rate(ORR) and disease control rate(DCR) in the observation group were 77.19%(44/57) and 61.40%(35/57), respectively, which were higher than those in the control group [57.89%(33/57) and 42.11%(24/57)](χ 2=4.842, 4.251, P=0.028, 0.039). After treatment, the levels of CD 3+ , CD 4+ cells and the ratio of CD 4+ /CD 8+ in the observation group were higher than those in the control group, while the level of CD 8+ cells in the observation group was lower than that in the control group, the differences were statistically significant( t=3.803, 4.538, 4.187, 6.042, P=0.000, 0.000, 0.000, 0.000). After treatment, the Skp2 protein level in the observation group was lower than that in the control group, and the p27kipl protein level in the observation groupwas higher than that in the control group, the differences were statistically significant( t=3.971, 4.110, P=0.000, 0.000). During the treatment, the incidences of adverse reactions in the observation group and the control group were 33.33%(19/57) and 24.56%(14/57), respectively, the difference between the two groups was statistically significant(χ 2=1.066, P=0.302). Conclusion:Ubenimex combined with FOLFOX4 can improve the immune function of patients with primary gastric cancer, regulate the expression of Skp2 and p27kipl protein, and has good therapeutic safety, which is worthy of clinical recommendation.
